Scarica l'app Stockscreener
2.83
3.28%
0.09
Dopo l'orario di chiusura:
3.01
0.18
+6.36%
Genprex Inc Borsa (GNPX) Ultime notizie
Genprex, Inc. Stock (GNPX) Opinions on Recent Preclinical Data Release - Quiver Quantitative
Is Genprex Inc. stock cheap at current valuationDollar Strength & Reliable Breakout Forecasts - Newser
Will Genprex Inc. (2DE0) stock recover faster than industryJuly 2025 Macro Moves & Reliable Volume Spike Trade Alerts - Newser
Why Genprex Inc. stock remains on buy listsWeekly Profit Summary & Safe Capital Investment Plans - Newser
Can Genprex Inc. stock beat market expectations this quarterMarket Activity Recap & Stepwise Entry/Exit Trade Alerts - BỘ NỘI VỤ
How Genprex Inc. (2DE0) stock reacts to new regulations2025 Market Trends & Daily Volume Surge Signals - BỘ NỘI VỤ
Genprex regains Nasdaq bid price compliance, receives equity extension By Investing.com - Investing.com Canada
Genprex regains Nasdaq bid price compliance, receives equity extension - Investing.com
Genprex reports phase 1 data for lung cancer gene therapy By Investing.com - Investing.com Nigeria
Data from Genprex's Acclaim-1 Phase 1 Gene Therapy Clinical Tria - GuruFocus
Genprex (GNPX) Shares Positive Acclaim-1 Trial Data for Lung Can - GuruFocus
Genprex reports phase 1 data for lung cancer gene therapy - Investing.com
Data from Genprex's Acclaim-1 Phase 1 Gene Therapy Clinical Trial Published in Clinical Lung Cancer - cnhinews.com
Genprex files prospectus supplement for up to $75 million at-the-market offering By Investing.com - Investing.com Australia
Genprex files prospectus supplement for up to $75 million at-the-market offering - Investing.com Australia
Genprex Inc. (GNPX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Genprex Announces $75 Million Stock Offering - MSN
[S-1] Genprex, Inc. Files IPO Registration Statement | GNPX SEC FilingForm S-1 - Stock Titan
Genprex, Inc. Announces $75 Million Stock Offering - TradingView
[8-K] Genprex, Inc. Reports Material Event | GNPX SEC FilingForm 8-K - Stock Titan
Can Genprex Inc. (2DE0) stock sustain revenue momentumWeekly Stock Summary & Safe Swing Trade Setup Alerts - newser.com
How Genprex Inc. stock benefits from tech adoption2025 Valuation Update & Reliable Volume Spike Trade Alerts - newser.com
Is Genprex Inc. stock attractive for retirement portfoliosJuly 2025 Breakouts & High Conviction Trade Alerts - newser.com
Why Genprex Inc. (2DE0) stock attracts wealthy investorsPortfolio Gains Summary & Fast Gain Swing Trade Alerts - newser.com
Is Genprex Inc. (2DE0) stock at risk of policy regulationWeekly Profit Report & Expert Approved Momentum Trade Ideas - newser.com
Will Genprex Inc. (2DE0) stock outperform global peersJuly 2025 Gainers & Consistent Growth Equity Picks - newser.com
Published on: 2025-11-19 22:26:30 - newser.com
Is Genprex Inc. (2DE0) stock undervalued at current priceWeekly Profit Analysis & Growth Focused Investment Plans - newser.com
Can Genprex Inc. (2DE0) stock reach $200 price targetJuly 2025 Retail & Short-Term Trading Alerts - newser.com
Will Genprex Inc. stock reach Wall Street targets2025 Technical Patterns & Long-Term Growth Portfolio Plans - newser.com
Will Genprex Inc. (2DE0) stock remain on Wall Street radarBull Run & Real-Time Chart Breakout Alerts - newser.com
Published on: 2025-11-19 13:34:52 - newser.com
Can Genprex Inc. (2DE0) stock beat analyst consensusEntry Point & Free Verified High Yield Trade Plans - newser.com
MSN Money - MSN
Genprex Adds Clinical Trial Site for Acclaim-1 and Acclaim-3 Lun - GuruFocus
Genprex Expands Clinical Trials with New Site Addition - TipRanks
Genprex Expands Clinical Trials for Lung Cancer Therapy - TradingView
Genprex Adds Clinical Trial Site for Acclaim-1 and Acclaim-3 Lung Cancer Clinical Trials - PR Newswire
0.18%
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):